Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Revenue (2018 - 2025)

Arcturus Therapeutics Holdings' Revenue history spans 8 years, with the latest figure at $7.2 million for Q4 2025.

  • For Q4 2025, Revenue fell 68.39% year-over-year to $7.2 million; the TTM value through Dec 2025 reached $82.0 million, down 46.14%, while the annual FY2025 figure was $82.0 million, 46.14% down from the prior year.
  • Revenue reached $7.2 million in Q4 2025 per ARCT's latest filing, down from $17.2 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $160.3 million in Q4 2022 to a low of $2.0 million in Q2 2021.
  • Average Revenue over 5 years is $31.0 million, with a median of $24.9 million recorded in 2022.
  • Peak YoY movement for Revenue: skyrocketed 2666.53% in 2022, then crashed 80.75% in 2023.
  • A 5-year view of Revenue shows it stood at $5.8 million in 2021, then surged by 2666.53% to $160.3 million in 2022, then plummeted by 80.75% to $30.9 million in 2023, then fell by 26.22% to $22.8 million in 2024, then tumbled by 68.39% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Revenue are $7.2 million (Q4 2025), $17.2 million (Q3 2025), and $28.3 million (Q2 2025).